About Us

Board of Directors

Board of Directors

Board of Directors

  • Mike Clayman, MD

    Chairman, Anokion
    CEO, Flexion Therapeutics

    Dr. Clayman is a co-founder of Flexion Therapeutics and has served as President, Chief Executive Officer, and as a director of the company since its inception in 2007. Read More

  • Laura Brass, PhD, MBA

    Managing Director, Novartis Venture Fund

    Dr. Laura Brass is a Managing Director at NVF in Cambridge, MA, USA. Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics of live patient data for clinical research. Read More

  • John A. Hohneker, MD

    CEO and President

    Prior to joining Anokion as CEO, John was President of Research and Development at FORMA Therapeutics Inc., where he guided the company’s transition from a discovery-stage biotech to one with programs in clinical trials. Read More

  • Jeffrey Hubbell, PhD

    Co-founder, Chief Scientific Advisor

    Jeff is a professor and founder of the Institute of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne (Swiss Federal Institute of Technology, EPFL), and a professor at the Institute of Molecular Engineering at the University of Chicago. Read More

  • Nilesh Kumar, PhD

    Partner, Novo Ventures

    Nilesh has been with Novo Ventures (US) Inc. in Boston since 2015. Read More

  • Dhavalkumar Patel, MD, PhD

    Chief Scientific Officer, UCB SA

    Dhaval is a physician scientist who serves as an Executive Vice President and Chief Scientific Officer at UCB in Brussels, Belgium, and on the Boards of Directors for several biotech companies. Read More

  • André J. Mueller

    Biotechnology Advisor; Former Chairman, Addex Therapeutics

    André J. Mueller, (1944, Swiss), private investor and business consultant, has been involved in the financing, management and supervision of development stage biotech enterprises over three decades. Read More

  • Harry Welten

    Former Chief Financial Officer, Cytos AG

    Harry Welten, MBA, spent more than twenty years in international senior executive functions, sixtee of which as chief financial officer in biotechnology companies (privately as well as publicly held). Read More

  • Tom Woiwode, PhD

    Managing Director, Versant Ventures

    Tom has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 and a Managing Director since 2014. Read More